english.prescrire.org > Prescrire International > N°249 - June 2023

n°249

June 2023

Issue Contents
Editorial

Free  Good sources

p.143

Marketing Authorisations


Difelikefalin (Kapruvia°) in pruritus associated with chronic kidney disease

p.145-148
An option for patients experiencing major discomfort, despite the uncertainties

Paliperidone as 6-monthly injections (Byannli°)

p.148-149

Recombinant Beta variant covid-19 vaccine with adjuvant (Vidprevtyn Beta°), as a booster

p.149-150

Ivacaftor + tezacaftor + elexacaftor (Kaftrio°) in cystic fibrosis with at least one delta F508 mutation from 6 years of age

p.151-152

Dapagliflozin (Forxiga°) in type 2 diabetes from 10 years of age

p.152-153

Tisagenlecleucel (Kymriah°) in refractory or relapsed follicular lymphoma

p.153

Subcutaneous weekly methotrexate (Nordimet°) in Crohn's disease (continued)

p.153

Levonorgestrel-releasing intrauterine device (Mirena°): contraceptive efficacy for 8 years

p.154

Adverse Effects


Drug-induced impairment of lactation

p.155-158

Isotretinoin and other retinoids: diffuse idiopathic skeletal hyperostosis

p.158-159

Montelukast: nightmares

p.159

Medication errors in children

p.160

Iodinated contrast media: severe delayed cutaneous hypersensitivity reactions

p.161

Common stem: -caftor

p.161

Outlook


Proving a treatment's efficacy

p.162-165
Double-blind randomised comparative trials, the foundation of a rigorous scientific approach

EMA and the European Ombudsman react to Prescrire's article about EMA transparency

p.166

Free  The finances of Association Mieux Prescrire: 2022 annual report

p.167

Masthead


Free  Masthead

p.142

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe